Renato Sousa, DPM
Podiatrist · Los Angeles, CANPI 1679002455
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,959 of the $13,503 with a category attached, or 66.3%. 33 manufacturers reported payments, led by Stryker at 25.5% of the total. Reporting peaked in 2024 at $4,299 and has fallen 64.7% since, to $1,519 in 2025. Among podiatrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $54.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$3K
- Biotissue Holdings Inc.$3K
- Smith+Nephew$3K
- Micromed Inc$2K
- Arthrex$612
- Bioventus LLC$336
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,85314%
- Food & beverage$8,95966%
- Education$2,69120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 38 | $3,437 |
| Biotissue Holdings Inc. | 78 | $2,590 |
| Smith+Nephew | 54 | $2,569 |
| Micromed Inc | 4 | $2,404 |
| Arthrex | 6 | $612 |
| Bioventus LLC | 8 | $336 |
| Orthofix Medical, Inc. | 7 | $189 |
| Zimmer Biomet | 5 | $172 |
| AbbVie | 5 | $136 |
| Organogenesis Inc. | 6 | $131 |
| Convatec Inc. | 5 | $111 |
| Shockwave Medical, Inc | 1 | $86 |
| KCI USA, Inc. | 4 | $81 |
| Hartmann USA, Inc. | 2 | $69 |
| Kerecis Limited | 2 | $66 |
| Integra Lifesciences Corporation | 2 | $59 |
| Johnson & Johnson | 2 | $54 |
| Paragon 28, Inc. | 3 | $45 |
| UCB, Inc. | 1 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Solventum Corporation | 2 | $32 |
| Sanara Medtech Inc. | 1 | $28 |
| Amniox Medical, Inc. | 1 | $25 |
| Tenex Health Inc. | 1 | $25 |
| Access Pro Medical, LLC | 1 | $24 |
| Davol Inc. | 1 | $23 |
| Nevro Corp. | 1 | $21 |
| Innovation Technologies Inc | 1 | $19 |
| Bone Support Inc. | 1 | $17 |
| Stimlabs LLC | 1 | $15 |
| Medline Industries LP | 1 | $15 |
| Aroa Biosurgery Incorporated | 1 | $14 |
| DJO, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Stravix$1,119
- INBONE$1,012
- GRAFIX PL$973
- NEOX$733
- CLARIX$733
- INFINITY$604
- Oasis$253
- SALVATION$159
- FLEXBAND$154
- T2$139
- Grafix XC$137
- STRAVIX PL$137
- Exogen Ultrasound Bone Healing System$133
- AUGMENT INJECTABLE$123
- EASYFUSE$123
- ORTHOLOC 2 LAPIFUSE$123
- CITREFIX$123
- INFINITY ADAPTIS$120
- VALOR$114
- Grafix$111
How this compares
$13,503 in reported general payments places this provider in the 90th percentile of 721 podiatrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 56 | $38,455 |
| Ketoconazole | 869 | $28,216 |
| Clotrimazole | 477 | $15,350 |
| Ciclopirox | 564 | $11,432 |
| Lidocaine | 11 | $3,024 |
| Diclofenac Sodium | 66 | $2,516 |
| Doxycycline Hyclate | 134 | $1,120 |
| Ammonium Lactate | 44 | $992 |
| Gabapentin | 46 | $352 |
| Ciprofloxacin Hcl | 81 | $322 |
| Meloxicam | 157 | $278 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 21 | $177 |
| Methylprednisolone | 22 | $84 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $80 |
| Tramadol Hcl | 29 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $2,569 | $38,45556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 721 podiatrist providers in California.
Other podiatrist in Los Angeles
- David ArmstrongLos Angeles$695K
- Charles AnanianLos Angeles$69K
- Edward KimLos Angeles$48K
- Benjamin McGrathLos Angeles$25K
- Laura ShinLos Angeles$20K
- Megan IshibashiLos Angeles$10K
- Shannon RushPleasanton$1.9M
- Babak BaravarianSanta Monica$1.1M
- Robert KleimanCalexico$913K
- Bruce LawrenceOceanside$810K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.